Clinical perspective: Have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology

Journal of Clinical Lipidology

Volumn 5, Issue 3, 2011, Pages 124-132

  Santos, Raul D ^a   Lorenzatti, Alberto J ^b,c   Barros, Carlos Fernandez ^d   Escobar, Edgardo ^e  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL PRIVADO   (Argentina)

^c Rusculleda Foundation for Research   (Argentina)

^d Hospital Ángeles   (Mexico)

^e UNIVERSITY OF CHILE   (Chile)

Author keywords

Biomarkers; C reactive protein; Cardiovascular disease; Coronary calcification; Hypercholesterolemia; LDL C; Surrogate end points

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PACTIMIBE; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CORONARY ARTERY; CORONARY ARTERY CALCIFICATION; DRUG EFFICACY; DRUG MONITORING; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERLIPIDEMIA; INTRAVASCULAR ULTRASOUND; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DYSLIPIDEMIAS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPOLIPIDEMIC AGENTS; LATIN AMERICA; LIPOPROTEINS, LDL; RISK FACTORS;

EID: 79956263380     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.02.006     Document Type: Conference Paper

References (52)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143-3421
2. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
3. H. Buchwald, R.L. Varco, and J.P. Matts Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) N Engl J Med 323 1990 946 955 (Pubitemid 20332334)
4. T.R. Pedersen, A.G. Olsson, and O. Faergeman Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation 97 1998 1453 1460 (Pubitemid 28191300)
5. R.B. Shekelle, and J. Stamler Dietary cholesterol and ischaemic heart disease Lancet 1 1989 1177 1179
6. Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims - Final. Available at: http://www.fda.gov/Food/ GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodLabelingNutrition/ ucm073332.htm. Accessed March 21, 2011.
7. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Lancet 376 2010 1670 1681
8. R.D. Santos, and K. Nasir Insights into atherosclerosis from invasive and non-invasive imaging studies: should we treat subclinical atherosclerosis? Atherosclerosis 205 2009 349 356
9. D.I. Buckley, R. Fu, M. Freeman, K. Rogers, and M. Helfand C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force Ann Intern Med 151 2009 483 495
10. R. Temple Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282 1999 790 795 (Pubitemid 29404390)
11. R. Duivenvoorden, A.J. Nederveen, E. de Groot, and J.J. Kastelein Atherosclerosis imaging as a benchmark in the development of novel cardiovascular drugs Curr Opin Lipidol 18 2007 613 621 (Pubitemid 350098565)
12. L.R. Martinez, M.H. Miname, and L.A. Bortolotto No correlation and low agreement of imaging and inflammatory atherosclerosis' markers in familial hypercholesterolemia Atherosclerosis 200 2008 83 88
13. P. Raggi, M. Davidson, and T.Q. Callister Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) Circulation 112 2005 563 571 (Pubitemid 41060797)
14. The CASHMERE Study. Pfizer, Inc. Available at: http://www. clinicalstudyresults.org/documents/company-study-2902-0.pdf. Accessed May 14, 2009.
15. J.J. Kastelein, F. Akdim, and E.S. Stroes Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 2008 1431 1443 (Pubitemid 351482735)
16. P.M. Ridker, E. Danielson, and F.A. Fonseca Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of Rosuvastatin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
17. M. Naghavi, E. Falk, and H.S. Hecht From vulnerable plaque to vulnerable patient-Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report Am J Cardiol 98 2006 2H 15H
18. R.D. Santos, K. Nasir, and J.A. Rumberger Difference in atherosclerosis burden in different nations and continents assessed by coronary artery calcium Atherosclerosis 187 2006 378 384 (Pubitemid 43963019)
19. M.J. Budoff, L.J. Shaw, and S.T. Liu Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients J Am Coll Cardiol 49 2007 1860 1870 (Pubitemid 46661110)
20. P. Raggi, T.Q. Callister, and L.J. Shaw Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy Arterioscler Thromb Vasc Biol 24 2004 1272 1277 (Pubitemid 38880020)
21. M. Romanens, F. Ackermann, and J.D. Spence Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics Eur J Cardiovasc Prev Rehabil 17 2010 18 23
22. R. Erbel, S. Möhlenkamp, and S. Moebus Heinz Nixdorf Recall Study Investigative Group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study J Am Coll Cardiol 56 2010 1397 1406
23. T.S. Polonsky, R.L. McClelland, and N.W. Jorgensen Coronary artery calcium score and risk classification for coronary heart disease prediction JAMA 303 2010 1610 1616
24. S.J. Nicholls, E.M. Tuzcu, and I. Sipahi Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 297 2007 499 508 (Pubitemid 46220805)
25. S.J. Nicholls, E.M. Tuzcu, and K. Wolski Coronary artery calcification and changes in atheroma burden in response to established medical therapies J Am Coll Cardiol 49 2007 263 270 (Pubitemid 46054402)
26. P. Schoenhagen, K.M. Ziada, S.R. Kapadia, T.D. Crowe, S.E. Nissen, and E.M. Tuzcu Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study Circulation 101 2000 598 603 (Pubitemid 30094729)
27. A.J. Taylor, S.M. Kent, and P.J. Flaherty ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness Circulation 106 2002 2055 2060 (Pubitemid 35192810)
28. A.J. Taylor, L.E. Sullenberger, H.J. Lee, J.K. Lee, and K.A. Grace Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517 (Pubitemid 39612564)
29. T.J. Smilde, S. van Wissen, H. Wollersheim, M.D. Trip, J.J. Kastelein, and A.F. Stalenhoef Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial Lancet 357 2001 577 581 (Pubitemid 32179609)
30. M.C. Meuwese, E. de Groot, and R. Duivenvoorden ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial JAMA 301 2009 1131 1139
31. J.R. Crouse 3rd, J.S. Raichlen, and W.A. Riley Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial JAMA 297 2007 1344 1353 (Pubitemid 46513235)
32. M. Vergeer, M.L. Bots, and S.I. van Leuven Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials Circulation 118 2008 2515 2522
33. M.L. Bots, F.L. Visseren, and G.W. Evans Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 2007 153 160 (Pubitemid 47042895)
34. J.L. Fleg, M. Mete, and B.V. Howard Effect of statins alone versus statins plus Ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial J Am Coll Cardiol 52 2008 2198 2205
35. B.V. Howard, M.J. Roman, and R.B. Devereux Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial JAMA 299 2008 1678 1689 (Pubitemid 351519865)
36. M.W. Lorenz, H.S. Markus, M.L. Bots, M. Rosvall, and M. Sitzer Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis Circulation 115 2007 459 467 (Pubitemid 46184197)
37. V. Nambi, L. Chambless, and A.R. Folsom Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study J Am Coll Cardiol 55 2010 1600 1607
38. J.H. Stein, C.E. Korcarz, and R.T. Hurst American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine J Am Soc Echocardiogr 21 2008 93 111 (Pubitemid 351193107)
39. S. van Wissen, T.J. Smilde, M.D. Trip, A.F. Stalenhoef, and J.J. Kastelein Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia Am J Cardiol 95 2005 264 266 (Pubitemid 40092097)
40. T.J. Smilde, M.D. Trip, H. Wollersheim, S. van Wissen, J.J.P. Kastelein, and A.F.H. Stalenhoef Rationale, design and baseline characteristics of a clinical trial comparing the effect of robust vs. conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolemia: the atorvastatin versus simvastatin on atherosclerosis progression (ASAP) study Clin Drug Invest 20 2000 67 79
41. C.P. Cannon, R.P. Giugliano, and Blazing MA IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Am Heart J 156 2008 826 832
42. Sharp Collaborative Group Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease Am Heart J 160 2010 785 794
43. S. Kaptoge, E. Di Angelantonio, G. Lowe Emerging Risk Factors Collaboration C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis Lancet 375 2010 132 140
44. P.M. Ridker, N.P. Paynter, N. Rifai, J.M. Gaziano, and N.R. Cook C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds Risk Score for Men Circulation 118 2008 2243 2251
45. P.T. Sager, L. Melani, L. Lipka, J. Strony, B. Yang, R. Suresh, and E. Veltri Effect of coadministration of Ezetimibe and simvastatin on high-sensitivity C-reactive protein Am J Cardiol 92 2003 1414 1418 (Pubitemid 37532562)
46. J. Bonnet, R. McPherson, and A. Tedgui Comparative effects of 10-mg versus 80-mg atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study Clin Ther 30 2008 2298 2313
47. M.H. Miname, and R.D. Santos Use of C-reactive protein to prevent atherosclerosis: between Jupiter and Mars Rev Assoc Med Bras 55 2009 502 504
48. Department of Health and Human Services. Memorandum. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM193831.pdf. Accessed December 10, 2010.
49. J. Genest, R. McPherson, and J. Frohlich 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 25 2009 567 579
50. P.M. Ridker, C.P. Cannon, and D. Morrow C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28 (Pubitemid 40075677)
51. P.M. Ridker, E. Danielson, and F.A. Fonseca JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
52. P.M. Ridker Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT) J Thromb Haemost 7 Suppl 1 2009 332 339